$44.33
1.14% yesterday
Nasdaq, Dec 29, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock price

$44.33
+0.82 1.88% 1M
+13.03 41.63% 6M
+5.13 13.09% YTD
+5.80 15.05% 1Y
+5.16 13.17% 3Y
+29.92 207.63% 5Y
+36.30 452.05% 10Y
+33.83 322.19% 20Y
Nasdaq, Closing price Mon, Dec 29 2025
-0.51 1.14%
ISIN
CA98420N1050
Symbol
XENE
Industry

Key metrics

Basic
Market capitalization
$3.5b
Enterprise Value
$3.0b
Net debt
positive
Cash
$462.3m
Shares outstanding
77.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
463.8 | 452.8
EV/Sales
402.1 | 392.6
EV/FCF
negative
P/B
6.2
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-59.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.7m
EBITDA
$-338.2m | $-368.8m
EBIT
$-340.8m | $-367.2m
Net Income
$-306.3m | $-333.6m
Free Cash Flow
$-253.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-33.8% | -33.3%
EBIT
-33.4% | -31.5%
Net Income
-43.6% | -42.4%
Free Cash Flow
-53.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,509.5% | -4,801.0%
EBIT
-4,543.7%
Net
-4,084.5% | -4,342.5%
Free Cash Flow
-3,377.2%
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
8.3%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 76 76
19% 19%
1,008%
- Research and Development Expense 273 273
42% 42%
3,636%
-338 -338
34% 34%
-4,510%
- Depreciation and Amortization 2.57 2.57
8% 8%
34%
EBIT (Operating Income) EBIT -341 -341
33% 33%
-4,544%
Net Profit -306 -306
44% 44%
-4,084%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
12 days ago
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercia...
Neutral
Seeking Alpha
19 days ago
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Neutral
GlobeNewsWire
24 days ago
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ...
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today